Informações:
Falhas:
ID
31073
Descrição
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00576758
Link
https://clinicaltrials.gov/show/NCT00576758
Palavras-chave
Versões (1)
- 17/07/2018 17/07/2018 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
17 de julho de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non-Hodgkin's Lymphoma NCT00576758
Eligibility Non-Hodgkin's Lymphoma NCT00576758
- StudyEvent: Eligibility
Similar models
Eligibility Non-Hodgkin's Lymphoma NCT00576758
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adult | Age
Item
adult patients, >=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
B-cell lymphoma recurrent CD20 positive indolent
Item
relapsed cd20+ indolent b-cell non-hodgkin's lymphoma
boolean
C0855089 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C0234227 (UMLS CUI [1,3])
C3888518 (UMLS CUI [1,2])
C0234227 (UMLS CUI [1,3])
Disease Response Due to Rituximab therapy
Item
documented history of response of >/= 6 months duration from last rituximab-containing regimen
boolean
C1704632 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C4047978 (UMLS CUI [1,3])
C0678226 (UMLS CUI [1,2])
C4047978 (UMLS CUI [1,3])
Indication Therapeutic procedure
Item
clinical indication for treatment as determined by the investigator
boolean
C3146298 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Monoclonal Antibodies Investigational
Item
prior use of any investigational monoclonal antibody within 6 months of study start
boolean
C0003250 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C1517586 (UMLS CUI [1,2])
Cancer Vaccines
Item
prior use of any anti-cancer vaccine
boolean
C0376659 (UMLS CUI [1])
Rituximab Use of Previous
Item
prior use of rituximab within 8 weeks of study entry
boolean
C0393022 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
C1524063 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Radioimmunotherapy
Item
radioimmunotherapy within 3 months prior to study entry
boolean
C0085101 (UMLS CUI [1])
Central nervous system lymphoma | Transformation High grade B-cell lymphoma | Transformation Diffuse Large B-Cell Lymphoma
Item
central nervous system (cns) lymphoma or evidence of transformation to high-grade or diffuse large b-cell lymphoma
boolean
C0742472 (UMLS CUI [1])
C0040682 (UMLS CUI [2,1])
C0456863 (UMLS CUI [2,2])
C0040682 (UMLS CUI [3,1])
C0079744 (UMLS CUI [3,2])
C0040682 (UMLS CUI [2,1])
C0456863 (UMLS CUI [2,2])
C0040682 (UMLS CUI [3,1])
C0079744 (UMLS CUI [3,2])